Cutting Edge: Reactive Oxygen Species Inhibitors Block Priming, but Not Activation, of the NLRP3 Inflammasome
Open accessThe DOI matches its Crossref record; 24 of the 25 references it cites were found in a registry or an index.
Abstract
A common denominator among the multiple damage-inducing agents that ultimately lead to activation of NLRP3 has not yet been identified. Recently, production of reactive oxygen species (ROS) has been suggested to act as a common event upstream of the NLRP3 inflammasome machinery. Because de novo translation of NLRP3 is an essential step in the activation of NLRP3, we investigated the role of substances that inhibit either ROS production or its oxidative activity. Although we observe that NLRP3 inflammasome activation is unique among other known inflammasomes in its sensitivity to ROS inhibition, we have found that this phenomenon is attributable to the fact that NLRP3 strictly requires priming by a proinflammatory signal, a step that is blocked by ROS inhibitors. Although these data do not exclude a general role for ROS production in the process of NLRP3-triggered inflammation, they would put ROS upstream of NLRP3 induction, but not activation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“As a result, these toxins mediate increased ROS production, which activates intrinsic apoptotic pathways and the NLRP3 inflammasome, thereby inflicting cytotoxicity in keratinocytes, neutrophils, and other tissue cells [14].”
From Role of Regulated Cell Death Pathways in Snakebite Envenomation: Mechanisms, Crosstalk, and Therapeutic Opportunities (2026) · cites this paper as [14]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A role for mitochondria in nlrp3 inflammasome activation
Zhou, R., Yazdi, A. S., Menu, P., & Tschopp, J. (2011) · Nature · doi:10.1038/nature09663 · Cited by 5,602
Gout-associated uric acid crystals activate the NALP3 inflammasome
Martinon, F., Pétrilli, V., Mayor, A., Tardivel, A., & Tschopp, J. (2006) · Nature · doi:10.1038/nature04516 · Cited by 5,326
Immunological and inflammatory functions of the interleukin-1 family
Dinarello, C. A. (2009) · Annual Review of Immunology · doi:10.1146/annurev.immunol.021908.132612 · Cited by 3,466 · cited 1×
“Owing to the highly proinflammatory potential of bioactive IL-1b, its release is a tightly controlled process, in which caspase-1–mediated cleavage of pro–IL-1b is a rate-limiting step (1).”
BackgroundCryopyrin activates the inflammasome in response to toxins and ATP
Mariathasan, S., Weiss, D. S., Newton, K., McBride, J., O'Rourke, K., Roose-Girma, M., Lee, W. P., Weinrauch, Y., Monack, D. M., & Dixit, V. M. (2006) · Nature · doi:10.1038/nature04515 · Cited by 3,080
Nakahira, K., Haspel, J. A., Rathinam, V. A. K., Lee, S.-J., Dolinay, T., Lam, H. C., Englert, J. A., Rabinovitch, M., Cernadas, M., Kim, H. P., et al. (2011) · Nature Immunology · doi:10.1038/ni.1980 · Cited by 3,049 · cited 1×
“To this effect, it has also been demonstrated that inhibitors of mitochondrial ROS production (17) and the knocking down of mitochondrial respiration by targeting the expression of voltage-dependent anion channels (18) downmodulate NLRP3-mediated inflammasome activation.”
BackgroundBauernfeind, F. G., Horvath, G., Stutz, A., Alnemri, E. S., MacDonald, K., Speert, D., Fernandes-Alnemri, T., Wu, J., Monks, B. G., Fitzgerald, K. A., et al. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0901363 · Cited by 2,959 · cited 4×
“Macrophages stably overexpressing NLRP3 were obtained through lentiviral transduction, as explained earlier (10).”
BackgroundMethodSelf-citationInnate Immune Activation Through Nalp3 Inflammasome Sensing of Asbestos and Silica
Dostert, C., Pétrilli, V., Van Bruggen, R., Steele, C., Mossman, B. T., & Tschopp, J. (2008) · Science · doi:10.1126/science.1156995 · Cited by 2,658
AIM2 recognizes cytosolic dsDNA and forms a caspase-1-activating inflammasome with ASC
Hornung, V., Ablasser, A., Charrel-Dennis, M., Bauernfeind, F., Horvath, G., Caffrey, D. R., Latz, E., & Fitzgerald, K. A. (2009) · Nature · doi:10.1038/nature07725 · Cited by 2,627
Self-citationAIM2 activates the inflammasome and cell death in response to cytoplasmic DNA
Fernandes-Alnemri, T., Yu, J.-W., Datta, P., Wu, J., & Alnemri, E. S. (2009) · Nature · doi:10.1038/nature07710 · Cited by 1,831
Kamata, H., Honda, S.-I., Maeda, S., Chang, L., Hirata, H., & Karin, M. (2005) · Cell · doi:10.1016/j.cell.2004.12.041 · Cited by 1,792
Cited by
Items 301–400 of 676
Alharthi, J., Bayoumi, A., Thabet, K., Pan, Z., Gloss, B., Latchoumanin, O., Lundberg, M., Twine, N. A., McLeod, D. J., Alenizi, S., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-35158-9 · Cited by 53
Zhang, X., Zheng, Y., Wang, Z., Gan, J., Yu, B., Lu, B., & Jiang, X. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.115475 · Cited by 52
Hua, K., Yang, F., Chiu, H., Chou, J., Dong, W.-C., Lin, C.-N., Lin, C.-Y., Wang, J., Li, L.-H., Chiu, H.-W., et al. (2015) · Infection and Immunity · doi:10.1128/iai.00125-15 · Cited by 52
“ROS contribute to NLRP3 inflammasome activation, as ROS inhibitor inhibits the priming signal of the NLRP3 inflammasome in LPS-activated macrophages (27, 30).”
BackgroundInfluentialPurinergic receptors: new targets for the treatment of gout and fibrosis
Gicquel, T., Daré, B. L., Boichot, E., & Lagente, V. (2016) · Fundamental and Clinical Pharmacology · doi:10.1111/fcp.12256 · Cited by 52
Inflammasomes in cardiovascular diseases.
Garg, N. J. (2011) · Europe PMC (PubMed Central) · Cited by 52
Li, S., Liang, F., Kwan, K., Tang, Y., Wang, X., Tang, Y., Li, J., Yang, H., Chavan, S. S., Wang, H., et al. (2018) · Molecular Medicine · doi:10.1186/s10020-018-0006-9 · Cited by 51
Gu, C., Liu, S., Wang, H., & Dou, H. (2019) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2019.4163 · Cited by 51
“ROS generation is considered as a necessary condition for the activation of NLRP3 inflammasome (25).”
BackgroundThe role of annexin A1 in the modulation of the NLRP3 inflammasome
Galvão, I., de Carvalho, R. A., Vago, J. P., Silva, A. L. N., Carvalho, T. G., Antunes, M. M., Ribeiro, F. M., Menezes, G. B., Zamboni, D. S., Sousa, L. P., et al. (2020) · Immunology · doi:10.1111/imm.13184 · Cited by 51
Inflammasome activation in podocytes: a new mechanism of glomerular diseases
Xiong, W., Meng, X., & Zhang, C. (2020) · Inflammation Research · doi:10.1007/s00011-020-01354-w · Cited by 51
Zhang, Y., Tao, C.-H., Xuan, C., Jiang, J., & Cao, W. (2020) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2020/9542165 · Cited by 51
“Aberrant oxidative stress and high levels of ROS can activate TXNIP by releasing TXNIP from the TXNIP/TRX complex, which subsequently leads to the NLRP3 activation [64, 77, 78].”
BackgroundSharawy, M. H., & Serrya, M. S. (2020) · Life Sciences · doi:10.1016/j.lfs.2020.118454 · Cited by 51
Specific NLRP3 inflammasome inhibitors: promising therapeutic agents for inflammatory diseases
Vong, C. T., Tseng, H. H. L., Yao, P., Yu, H., Wang, S., Zhong, Z., & Wang, Y. (2021) · Drug Discovery Today · doi:10.1016/j.drudis.2021.02.018 · Cited by 51
Noncanonical Roles of Caspase-4 and Caspase-5 in Heme-Driven IL-1β Release and Cell Death
Bolívar, B. E., Brown-Suedel, A. N., Rohrman, B. A., Charendoff, C. I., Yazdani, V., Belcher, J. D., Vercellotti, G. M., Flanagan, J. M., & Bouchier‐Hayes, L. (2021) · The Journal of Immunology · doi:10.4049/jimmunol.2000226 · Cited by 50
NLRP3 inflammasome activation, metabolic danger signals, and protein binding partners
Leu, S., Tsang, Y.-L., Ho, L., Yang, C.-C., Shao, A., Chang, C.-Y., Lin, H.-K., Tsai, P.-J., Sung, J., & Tsai, Y.-S. (2023) · Journal of Endocrinology · doi:10.1530/joe-22-0184 · Cited by 50
Biofilm from a clinical strain of Cryptococcus neoformans activates the NLRP3 inflammasome
Lei, G., Chen, M., Li, H., Niu, J., Wu, S., Mao, L., Lu, A., Wang, H., Chen, W., Xu, B., et al. (2013) · Cell Research · doi:10.1038/cr.2013.49 · Cited by 50
Liu, Y., Yao, W., Jun, X., Qiu, Y., Cao, F., Li, S., Yang, S., Yang, H., Wu, Z., & Hou, Y. (2015) · Innate Immunity · doi:10.1177/1753425914566205 · Cited by 50
“ROS inhibitors block NLRP3 inflammasome activation by interfering with the priming step, which is required to induce NLRP3 expression, whereas direct NLRP3 activation is not affected.17 The present study showed that LPS stimulation significantly enhanced the mRNA expression and protein production of TNF-a, and suggest…”
BackgroundResultInfluentialGenipin suppresses NLRP3 inflammasome activation through uncoupling protein-2
Rajanbabu, V., Galam, L., Fukumoto, J., Enciso, J., Tadikonda, P., Lane, T., Bandyopadhyay, S., Parthasarathy, P. T., Cho, Y., Cho, S., et al. (2015) · Cellular Immunology · doi:10.1016/j.cellimm.2015.06.002 · Cited by 50
Mercury and arsenic attenuate canonical and non-canonical NLRP3 inflammasome activation
Ahn, H., Kim, J., Kang, S. G., Yoon, S., Ko, H., Kim, P.-H., Hong, E., An, B., Lee, E., & Lee, G. (2018) · Scientific Reports · doi:10.1038/s41598-018-31717-7 · Cited by 50
NLRP3 Inflammasome: A Potential Alternative Therapy Target for Atherosclerosis
Liu, Y., Li, C., Yin, H., Zhang, X., & Li, Y. (2020) · Evidence-based Complementary and Alternative Medicine · doi:10.1155/2020/1561342 · Cited by 50
“A study has shown that the priming of NLRP3 is inhibited when antioxidants block mtROS [51].”
BackgroundIsakov, E., Weisman-Shomer, P., & Benhar, M. (2014) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2014.07.012 · Cited by 50
“Overall, the extent to which the macrophage Trx/TrxR system affects TLR-dependent responses and the underlying mechanisms remains to be established.”
BackgroundInfluentialPitanga, T. N., Oliveira, R. R., Zanette, D. L., Guarda, C. C., Santiago, R. P., Santana, S. S., Nascimento, V. M. L., Lima, J. B., Carvalho, G. Q., Maffili, V. V., et al. (2016) · Cytokine · doi:10.1016/j.cyto.2016.03.016 · Cited by 49
Bengalli, R. D., Molteni, E., Longhin, E., Refsnes, M., Camatini, M., & Gualtieri, M. (2013) · BioMed Research International · doi:10.1155/2013/158093 · Cited by 49
Chen, G., Wang, X., Severo, M. S., Sakhon, O. S., Sohail, M., Brown, L. J., Sircar, M., Snyder, G. A., Sundberg, E. J., Ulland, T. K., et al. (2014) · Infection and Immunity · doi:10.1128/iai.01679-14 · Cited by 49
“DPI may produce off-target effects at high concentrations (42).”
BackgroundInfluentialMa, C., Liu, S., Zhang, S., Xu, T., Yu, X. L., Gao, Y., Zhai, C., Li, C., Lei, C., Fan, S., et al. (2018) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2018.3911 · Cited by 49
NLR activation takes a direct route
Monie, T. P. (2013) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2013.01.001 · Cited by 48
Lee, J. Y., Seo, D., You, J., Chung, S., Park, J. S., Lee, J.-H., Jung, S. M., Lee, Y. S., & Park, S. H. (2017) · FEBS Letters · doi:10.1002/1873-3468.12558 · Cited by 49
Atluri, V. S. R., Pilakka‐Kanthikeel, S., Garcia, G., Jayant, R. D., Sagar, V., Samikkannu, T., Yndart, A., & Nair, M. (2016) · Scientific Reports · doi:10.1038/srep27864 · Cited by 48
Complement activation by cholesterol crystals triggers a subsequent cytokine response
Niyonzima, N., Halvorsen, B. L., Sporsheim, B., Garred, P., Aukrust, P., Mollnes, T. E., & Espevik, T. (2016) · Molecular Immunology · doi:10.1016/j.molimm.2016.09.019 · Cited by 48
Peng, Y., Guo, Y., Ge, X., Gong, Y., Wang, Y., Ou, Z., Luo, G., Zhan, R., & Zhang, Y. (2024) · Journal of Nanobiotechnology · doi:10.1186/s12951-024-02390-y · Cited by 47
“NLRP3 could lead to the maturation of proinflammatory factors [42], such as IL-1β and IL-18, and the decreased concentration of IL-1β following PTMH treatment (Fig.”
BackgroundTrendelenburg, G. (2014) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/jcbfm.2014.159 · Cited by 47
Erttmann, S. F., Härtlová, A., Słoniecka, M., Raffi, F. A. M., Hosseinzadeh, A., Edgren, T., Rofougaran, R., Resch, U., Fällman, M., Ek, T., et al. (2016) · Immunity · doi:10.1016/j.immuni.2016.06.018 · Cited by 47
“However, the positive regulatory effects previously ascribed to ROS have recently been shown to be due to its role in priming via transcriptional and non-transcriptional mechanisms (Bauernfeind et al., 2011; Juliana et al., 2012; van de Veerdonk et al., 2010).”
BackgroundInfluentialFu, S., Liu, H., Xu, L., Qiu, Y., Liu, Y., Wu, Z., Ye, C., Hou, Y., & Hu, C. A. (2018) · Scientific Reports · doi:10.1038/s41598-018-19293-2 · Cited by 47
Márquez, J. D. R., Ana, Y., Baigorrí, R. E., Stempin, C. C., & Cerbán, F. M. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00313 · Cited by 48
Priming of NLRP3 inflammasome activation by Msn kinase MINK1 in macrophages
Zhu, K., Jin, X., Chi, Z., Chen, S., Wu, S., Sloan, R. D., Lin, X., Neculai, D., Wang, D., Hu, H., et al. (2021) · Cellular and Molecular Immunology · doi:10.1038/s41423-021-00761-1 · Cited by 47
Wu, C.-Y., Hua, K., Hsu, W., Suzuki, Y., Chu, L. J., Lee, Y., Takahata, A., Lee, S.-L., Wu, C., Nikolic‐Paterson, D. J., et al. (2020) · The Journal of Immunology · doi:10.4049/jimmunol.1900284 · Cited by 46
Anxiolytic effects of NLRP3 inflammasome inhibition in a model of chronic sleep deprivation
Smith, C., Trageser, K. J., Wu, H., Herman, F. J., Iqbal, U. H., Sebastian-Valverde, M., Frolinger, T., Zeng, E., & Pasinetti, G. M. (2021) · Translational Psychiatry · doi:10.1038/s41398-020-01189-3 · Cited by 43
Qin, N., Xu, G., Wang, Y., Zhan, X., Gao, Y., Wang, Z., Fu, S., Shi, W., Hou, X., Wang, C., et al. (2021) · Frontiers of Medicine · doi:10.1007/s11684-020-0809-2 · Cited by 46
Chakraborty, R., Tabassum, H., & Parvez, S. (2022) · Life Sciences · doi:10.1016/j.lfs.2022.121352 · Cited by 46
Ka, S., Chao, L. K., Lin, J., Chen, S., Li, W., Lin, C.-N., Cheng, J.-C., Jheng, H.-L., Chen, A., & Hua, K. (2015) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2015.12.003 · Cited by 45
Review: Beyond the NLRP3 Inflammasome: Autoinflammatory Diseases Reach Adolescence
Gattorno, M., & Martini, A. (2013) · Arthritis & Rheumatism · doi:10.1002/art.37882 · Cited by 45
Prager, P., Hollborn, M., Steffen, A., Wiedemann, P., Kohen, L., & Bringmann, A. (2016) · PLoS ONE · doi:10.1371/journal.pone.0165653 · Cited by 44
Application of Disulfiram and its Metabolites in Treatment of Inflammatory Disorders
Guo, W., Chen, S., Li, C., Xu, J., & Wang, L. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.795078 · Cited by 44
The Role of Reactive Oxygen Species (ROS) in Periodontitis: A Potential Therapeutic Target
Yang, S., & Yang, X. (2025) · Immunity Inflammation and Disease · doi:10.1002/iid3.70301 · Cited by 44
“Previous studies reported that ROS are essential for initiating NLRP3 activation but not necessary for sustaining it [161].”
Mapping Txnip: Key connexions in progression of diabetic nephropathy
Kumar, A., & Mittal, R. (2017) · Pharmacological Reports · doi:10.1016/j.pharep.2017.12.008 · Cited by 43
Westfall, S., Iqbal, U., Sebastian, M., & Pasinetti, G. M. (2019) · Progress in Molecular Biology and Translational Science · doi:10.1016/bs.pmbts.2019.06.013 · Cited by 41
Contradictory Effects of NLRP3 Inflammasome Regulatory Mechanisms in Colitis
Wagatsuma, K., & Nakase, H. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21218145 · Cited by 42
“On the other hand, it has been reported that ROS inhibitors block priming of the NLRP3 inflammasome but not its activation [24].”
BackgroundBaragetti, A., Catapano, A. L., & Magni, P. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21124459 · Cited by 41
“In some reports, pharmacologically blocking mitochondrial respiratory chain (in vitro by pyridaben) blunts the ROS intracellular levels, resulting in the inhibition of NLRP3 [31], non-transcriptional activation, whereas, in others, ROS production has been found to be essential for NLRP3 priming but not activation upon…”
BackgroundInfluentialLiao, Y., Kong, Y., Chen, H., Xia, J., Zhao, J., & Zhou, Y. (2024) · International Immunopharmacology · doi:10.1016/j.intimp.2024.113821 · Cited by 39
Kankkunen, P., Välimäki, E., Rintahaka, J., Palomäki, J., Nyman, T. A., Alenius, H. T., Wolff, H. J., & Matikainen, S. (2013) · Human Immunology · doi:10.1016/j.humimm.2013.11.010 · Cited by 39
NLPR3 Inflammasomes and Their Significance for Atherosclerosis
Poznyak, A. V., Melnichenko, A. А., Wetzker, R., Герасимова, Е. В., & Orekhov, A. N. (2020) · Biomedicines · doi:10.3390/biomedicines8070205 · Cited by 39
“Some scientists propose that ROS scavengers (as N-acetyl-lysine (NAC)) do not influence the direct activation of NLRP3 by classical NLRP3 agonists, although they stop the transcription of NLRP3 and pro-IL-1β [40].”
BackgroundQuercetin ameliorates XIAP deficiency–associated hyperinflammation
Chiang, S. C. C., Owsley, E., Panchal, N., Chaturvedi, V., Terrell, C. E., Jordan, M. B., Mehta, P. A., Davies, S. M., Akeno, N., Booth, C., et al. (2022) · Blood · doi:10.1182/blood.2021014335 · Cited by 39
Inflammasome Complexes: Crucial mediators in osteoimmunology and bone diseases
Zhou, F., Zhang, G., Wu, Y., & Xiong, Y. (2022) · International Immunopharmacology · doi:10.1016/j.intimp.2022.109072 · Cited by 39
Mitochondrial Contribution to Inflammation in Diabetic Kidney Disease
Mitrofanova, A. V., Fontanella, A. M., Burke, G. W., Merscher, S., & Fornoni, A. (2022) · Cells · doi:10.3390/cells11223635 · Cited by 39
TRIM34 attenuates colon inflammation and tumorigenesis by sustaining barrier integrity
Lian, Q., Yan, S., Yin, Q., Yan, C., Zheng, W., Gu, W., Zhao, X., Fan, W., Li, X., Ma, L., et al. (2020) · Cellular and Molecular Immunology · doi:10.1038/s41423-020-0366-2 · Cited by 38
Welcome, M. O., & Mastorakis, N. E. (2021) · Pharmacological Research · doi:10.1016/j.phrs.2021.105557 · Cited by 38
Effector functions of NLRs in the intestine: innate sensing, cell death, and disease
Yeretssian, G. (2012) · Immunologic Research · doi:10.1007/s12026-012-8317-3 · Cited by 37
“However, ROS production seems to regulate the priming step of NLRP3 inflammasome activation and does not directly affect the inflammasome formation [128].”
BackgroundSugita, K., Ikenouchi, A., Nakayama, Y., Yoshioka, H., Nomura, T., Sakabe, J., Nakahigashi, K., Kuroda, E., Uematsu, S., Nakamura, J., et al. (2013) · Scientific Reports · doi:10.1038/srep02973 · Cited by 37
Zheng, T., Tan, Y., Qiu, J., Xie, Z., Hu, X., Zhang, J., & Na, N. (2021) · Cell Death and Disease · doi:10.1038/s41419-021-03751-3 · Cited by 37
Ye, C., Li, S., Yao, W., Xu, L., Qiu, Y., Liu, Y., Wu, Z., & Hou, Y. (2016) · Innate Immunity · doi:10.1177/1753425916631032 · Cited by 37
“In this study, it has been found that after 3 h of LPS stimulation, the mRNA expression of NLRP3 was significantly increased, while there were no significant differences for the ASC and caspase-1 genes, similar to the report by Bauernfeind et al.(38) ASC was redistributed to achieve the assembly of the NLRP3 inflammas…”
BackgroundResultInfluentialNLRP3 Inflammasome Activation in THP-1 Target Cells Triggered by Pathogenic Naegleria fowleri
Kim, J.-H., Sohn, H., Yoo, J.-K., Kang, H., Seong, G.-S., Chwae, Y., Kim, K. H., Park, S., & Shin, H. (2016) · Infection and Immunity · doi:10.1128/iai.00275-16 · Cited by 37
“A recent study has revealed that NADPH oxidase may play a role in inducing ROS and that ROS production is required to prime the NLRP3 inflammasome (32).”
BackgroundChronic allograft dysfunction: A model disorder of innate immunity
Land, W. G. (2013) · Biomedical Journal · doi:10.4103/2319-4170.117622 · Cited by 36
Lee, S., Kim, G., Kim, N. Y., Kim, S., Ghosh, P., & Rhee, D. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.01954 · Cited by 36
“This phenomenon either blocks NLRP3 priming or promotes cell death (35, 36).”
BackgroundOh, S., Son, M., Park, C. H., Jang, J. T., Son, K. H., & Byun, K. (2020) · Marine Drugs · doi:10.3390/md18120648 · Cited by 36
“DAMPs and free fatty acids activate TLRs [12] and lead to the upregulation of NF-κB, which results in increasing NLRP3 inflammasomes [13,14].”
BackgroundHuman pathogenic fungus Trichophyton schoenleinii activates the NLRP3 inflammasome
Li, H., Wu, S., Mao, L., Lei, G., Zhang, L., Lu, A., An, L., Yang, G., Abliz, P., & Meng, G. (2013) · Protein & Cell · doi:10.1007/s13238-013-2127-9 · Cited by 36
Li, M., Gunter, M. E., & Fukagawa, N. K. (2012) · Cytokine · doi:10.1016/j.cyto.2012.08.025 · Cited by 36
Feng, S., Zhang, Z., Mo, Y., Tong, R., Zhong, Z., Chen, Z., He, D., Wan, R., Gao, M., Mo, Y., et al. (2020) · Toxicology in Vitro · doi:10.1016/j.tiv.2020.104967 · Cited by 35
Chhunchha, B., Kubo, E., Lehri, D., & Singh, D. P. (2025) · Cells · doi:10.3390/cells14130994 · Cited by 35
“Earlier studies suggest that NLRP3 recognizes markers of mitochondrial dysfunction/disintegration, including ROS and mtDNA damage and release [150,237,240].”
Shen, J., Shen, D., Tang, Q., Li, Z., Jin, X., & Li, C. (2022) · Toxicology in Vitro · doi:10.1016/j.tiv.2022.105326 · Cited by 35
Effects of hydrogen-rich water on aging periodontal tissues in rats
Tomofuji, T., Kawabata, Y., Kasuyama, K., Endo, Y., Yoneda, T., Yamane, M., Azuma, T., Ekuni, D., & Morita, M. (2014) · Scientific Reports · doi:10.1038/srep05534 · Cited by 35
Obovatol inhibits NLRP3, AIM2, and non-canonical inflammasome activation
Kim, J., Ahn, H., Han, B.-C., Shin, H., Kim, J., Jung, E., Kim, J., Yang, H., Lee, J., Kang, S. G., et al. (2019) · Phytomedicine · doi:10.1016/j.phymed.2019.153019 · Cited by 35
The NLRP3 inflammasome: a therapeutic target for inflammation-associated cancers
Gouravani, M., Khalili, N., Razi, S., Keshavarz‐Fathi, M., Khalili, N., & Rezaei, N. (2020) · Expert Review of Clinical Immunology · doi:10.1080/1744666x.2020.1713755 · Cited by 35
“into the cytosol, resulting in activation of the inflammasome [49,50].”
BackgroundXu, L., An, T., Jia, B., Wu, Q., Shen, J., Jin, J., Liu, J., & Li, C. (2023) · Burns & Trauma · doi:10.1093/burnst/tkad062 · Cited by 34
Li, Y., Rasheed, M., Liu, J., Chen, Z., & Deng, Y. (2024) · Cells · doi:10.3390/cells13100863 · Cited by 34
The Roles of Inflammasomes in Host Defense against Mycobacterium tuberculosis
Ma, J., Zhao, S., Gao, X., Wang, R., Liu, J., Zhou, X., & Zhou, Y. (2021) · Pathogens · doi:10.3390/pathogens10020120 · Cited by 34
“LPS-primed cells pretreated with MTB H37Rv, but not ESAT-6 deletion mutant, secrets less IL-1β and IL-18 in response to M. smegmatis or poly(dA:dT), indicating that virulent MTB strains inhibits AIM2-dependent IL-1β release [152].”
BackgroundInfluentialApoptosis‐Sensitizing Tumor Nanomedicine by Regulating Pyroptosis‐Associated Inflammatory Cell Death
Du, F., Zhao, H., Song, Y., Feng, Z., Liu, K., Wang, Z., Guo, R., Li, Q., Chen, Q., & Zhou, L. (2024) · Advanced Functional Materials · doi:10.1002/adfm.202406150 · Cited by 34
Inflammasome Activation by Altered Proteostasis
Shin, J. N., Fattah, E. A., Bhattacharya, A., Ko, S., & Eissa, N. T. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.514919 · Cited by 34
“However, the role of ROS in inflammasome activation in general and the source of ROS implicated in such a role are more controversial (31, 32).”
BackgroundLi, C., Guo, S., Pang, W., & Zhao, Z. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2019.00378 · Cited by 34
“Chemical inhibitors are likely to cause off-target artifacts; a study shows that a high concentration of ROS inhibitors DPI or NAC affects the NLRP3 inflammasome in the priming stage (Bauernfeind et al., 2011).”
BackgroundBradfield, C. J., Liang, J. J., Ernst, O., John, S. P., Sun, J., Ganesan, S., de Jesus, A. A., Bryant, C. E., Goldbach-Mansky, R., & Fraser, I. D. C. (2023) · Cell Death & Differentiation · doi:10.1038/s41418-022-01106-9 · Cited by 33
“Meanwhile mtROS scavenging with mitoTEMPO limits ASC specking to levels observed following JNK inhibition, or deletion of the Jnk1 gene, and complements prior findings for mtROS during inflammasome activation [24, 26, 56].”
BackgroundMitochondrial dysfunction and NLRP3 inflammasome: key players in kidney stone formation
Su, B., Ren, Y., Yao, W., Su, Y., & He, Q. (2024) · British Journal of Urology · doi:10.1111/bju.16454 · Cited by 33
“With the application of ROS inhibitors, the expression of the NLRP3 in fl ammasome decreases, and cellular in fl ammatory damage is reduced, slowing the process of stone development [50,51].”
Ramos, E. L. P., Neto, I. V. D. S., Pinto, A. P., Cintra, D. E., Ropelle, E. R., Pauli, J., de Freitas, E. C., Mineo, T. W. P., & da Silva, A. S. R. (2025) · Ageing Research Reviews · doi:10.1016/j.arr.2025.102821 · Cited by 33
Hua, K., Chou, J., Lam, Y., Tasi, Y., Chen, A., Ka, S., Fang, Z., Liu, M.-L., Yang, F., Yang, Y., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0076754 · Cited by 33
“, from ATP) for caspase-1 activation and IL-1β secretion [40,41].”
BackgroundHasan, D., Blankman, P., & Nieman, G. F. (2017) · Purinergic Signalling · doi:10.1007/s11302-017-9564-5 · Cited by 33
“Note that the gene expression of IL-1β was not increased because ATP regulates the posttranscriptional activation of NLRP3 inflammasomes [152, 228, 229] , and this cannot be detected with the applied RT-PCR technique.”
MethodBilen, S., Biswas, G., Otsuyama, S., Kono, T., Sakai, M., & Hikima, J.-I. (2014) · Developmental & Comparative Immunology · doi:10.1016/j.dci.2014.04.010 · Cited by 32
Song, L., Huang, Y., Zhao, M., Wang, Z., Wang, S., Sun, H., Kan, B., Meng, G., Liang, W., & Ren, Z. (2015) · Frontiers in Microbiology · doi:10.3389/fmicb.2015.00510 · Cited by 32
Diphenyleneiodonium, an inhibitor of NOXes and DUOXes, is also an iodide‐specific transporter
Massart, C., Giusti, N., Beauwens, R., Dumont, J. E., Miot, F. E. L., & Sande, J. V. (2013) · FEBS Open Bio · doi:10.1016/j.fob.2013.11.007 · Cited by 32
NLRP3 inflammasome as therapeutic targets in inflammatory diseases
Prakash, A. V., Park, I.-H., Park, J. W., Bae, J. P., Lee, G. S., & Kang, T. J. (2023) · Biomolecules & Therapeutics · doi:10.4062/biomolther.2023.099 · Cited by 31
“Reactive oxygen species (ROS), mitochondrial DNA (mtDNA) also activates the NLRP3 and promote NLRP3 expression at the transcriptional level (Zhou et al., 2010; Bauernfeind et al., 2011b; Shimada et al., 2012).”
BackgroundInflammaging as the basis of age-associated diseases
Artemyeva, O. V., & Gankovskaya, L. V. (2020) · Medical Immunology (Russia) · doi:10.15789/1563-0625-iat-1938 · Cited by 31
Balow, J. E., Ryan, J., Chae, J. J., Booty, M. G., Bulua, A. C., Stone, D. L., Sun, H., Greene, J., Barham, B. K., Goldbach‐Mansky, R. T., et al. (2012) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2012-202082 · Cited by 31
“However, more recent data suggested the role for ROS in priming the expression of NLRP3 and not in the direct activation of the NLRP3 inflammasome.(23) The microarray data from CAPS patients versus healthy controls identified the altered expression of genes associated with the generation and propagation of ROS signall…”
BackgroundXiao-yu, Z., Liu, Z., Ying, K., Wang, H., Liu, P., Ji, X., Chi, T., Zou, L., Wang, S., & He, Z. (2020) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2020/7950457 · Cited by 31
Chao, L. K., Lin, C., Chiu, H.-W., Wong, W.-T., Chiu, H., Tasi, Y., Kuo, Y., Chiu, Y.-C., Liu, M.-L., Ho, C., et al. (2015) · Journal of Agricultural and Food Chemistry · doi:10.1021/jf5054436 · Cited by 30
Pauls, S. D., Rodway, L. A., Sidhu, K. K., Winter, T., Sidhu, N., Aukema, H. M., Zahradka, P. C., & Taylor, C. G. (2021) · Journal of Nutrition · doi:10.1093/jn/nxab235 · Cited by 30
An association between mitochondria and microglia effector function: what do we think we know?
Harry, G. J., Childers, G. M., Giridharan, S., & Hernandes, I. L. (2020) · Neuroimmunology and Neuroinflammation · doi:10.20517/2347-8659.2020.07 · Cited by 29
“At least one study reported that mtROS inhibitors do not block the secondary activation step, but rather the initial priming step([199]).”
BackgroundBai, L., Wu, C., Lei, S., Zou, M., Wang, S., Zhang, Z., Bao, Z., Ren, Z., Liu, K., Ma, Q., et al. (2023) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2023.116147 · Cited by 29
Varga, A., Budai, M. M., Milesz, S., Bácsi, A., Tőzsér, J., & Benkő, S. (2012) · Immunology · doi:10.1111/imm.12052 · Cited by 29
K+ Drops Tilt the NLRP3 Inflammasome
Kanneganti, T., & Lamkanfi, M. (2013) · Immunity · doi:10.1016/j.immuni.2013.06.001 · Cited by 29
Geranylgeraniol and Neurological Impairment: Involvement of Apoptosis and Mitochondrial Morphology
Marcuzzi, A., Piscianz, E., Zweyer, M., Bortul, R., Loganes, C., Girardelli, M., Baj, G., Monasta, L., & Celeghini, C. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms17030365 · Cited by 29
“Recent developments on the activation of NLRP3 and on damaged mitochondria, indicate that ROS produced by the dysfunction of mitochondria have a crucial role in priming NLRP3, even though the molecular mechanism underlying this process remains unclear [31,32].”
BackgroundNonsaponin fractions of Korean Red Ginseng extracts prime activation of NLRP3 inflammasome
Han, B.-C., Ahn, H., Lee, J., Jeon, E., Seo, S., Jang, K. H., Lee, S., Kim, C. H., & Lee, G. (2016) · Journal of Ginseng Research · doi:10.1016/j.jgr.2016.10.001 · Cited by 29
“LPS-mediated NLRP3 expression, as performed in the literature [10,16].”
BackgroundMethodDoktor, F., Prager, P., Wiedemann, P., Kohen, L., Bringmann, A., & Hollborn, M. (2018) · Purinergic Signalling · doi:10.1007/s11302-018-9631-6 · Cited by 29
Citrobacter freundii Activation of NLRP3 Inflammasome via the Type VI Secretion System
Liu, L., Song, L., Deng, R. X., Lan, R., Jin, W., Nhieu, G. T. V., Cao, H., Liu, Q., Xiao, Y., Li, X., et al. (2020) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiaa692 · Cited by 28
Quijano, A., Díaz-Ruiz, C., López-López, A., Villar‐Cheda, B., Muñoz, A., Rodriguez-Perez, A. I., & Labandeira-García, J. L. (2022) · Antioxidants · doi:10.3390/antiox11020329 · Cited by 28
“Interestingly, several studies have shown that NADPH-oxidase- and mitochondrial-derived ROS induce NLRP3 activation by acting particularly on the priming step [43,44], although the responsible mechanism requires further clarification.”
Background
Metadata
- Authors
- Bauernfeind, F., Bartok, E., Rieger, A., Franchi, L., Núñez, G., & Hornung, V.
- Affiliations
- University of Bonn (DE)
- University of Michigan (US)
- Corresponding author
- Bauernfeind, Franz
- Bartok, Eva
- Rieger, Anna
- Hornung, Veit
- Venue
- The Journal of Immunology
- Publisher
- Oxford University Press (OUP)
- Published
- 2011-07
- Volume
- 187
- Issue
- 2
- Pages
- 613-617
- ISSN
- 0022-1767 (ISSN-L)
- 1550-6606
- PMC
- PMC3131480
- OpenAlex
- W1756750202
- Cited by
- 617
- References
- 25
- Citations by year
- 2026: 21 · 2025: 33 · 2024: 41 · 2023: 32 · 2022: 43 · 2021: 32 · 2020: 48 · 2019: 36 · 2018: 41 · 2017: 26 · 2016: 41 · 2015: 50 · 2014: 46 · 2013: 70 · 2012: 45
- FWCI
- 22.44
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- The Journal of Immunology (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- MPG.PuRe (Max Planck Society) (submittedVersion)
- Funders
- Takeda Oncology
- National Institute of Allergy and Infectious Diseases (R01AI063331)
- National Institute of Diabetes and Digestive and Kidney Diseases (R01DK091191)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Inflammasome and immune disorders
- Life Sciences › Immunology and Microbiology › Immunology › Immune Response and Inflammation
- Life Sciences › Immunology and Microbiology › Immunology › Neutrophil, Myeloperoxidase and Oxidative Mechanisms
- Keywords
- NLRP3 inflammasome, reactive oxygen species, inflammasome priming, inflammasome activation
- MeSH terms
- NLR Family, Pyrin Domain-Containing 3 Protein, NADPH Oxidase 2, Animals, Biphenyl Compounds, Carrier Proteins, Cells, Cultured, Lymphocyte Activation, Macrophages, Membrane Glycoproteins, Mice, Inbred C57BL, Mice, Mutant Strains, Onium Compounds, Signal Transduction, Down-Regulation, Reactive Oxygen Species, NADPH Oxidases, STAT1 Transcription Factor, Mice, Inflammasomes
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.